WebinarsNew
Deep DiveNew
Explore Business Standard
Biocon Ltd on Tuesday said its subsidiary has received supplemental approval from the US health regulator for Yesintek prefilled autoinjector. Yesintek is indicated for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. The company's subsidiary in the United States has received supplemental US Food and Drug Administration (USFDA) approval for Yesintek of strengths 45 mg/0.5 ml single-dose prefilled autoinjector and 90 mg/ml single-dose prefilled autoinjector, Biocon said in a regulatory filing. Yesintek was originally approved by the USFDA on November 29, 2024, it added. The Yesintek single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs, the company said. Yesintek is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients
: Biocon Ltd on Wednesday said it has received notice of compliance approval from Canadian health regulator for its Yesintek (ustekinumab) autoinjector, indicated for the treatment of moderate to severe plaque psoriasis. The company's subsidiary in Canada has received Notice of Compliance (NOC) approval for Yesintek (ustekinumab) Autoinjector 45 mg/0.05 mL and 90 mg/mL from Health Canada, Biocon Ltd said in a regulatory filing. Health Canada previously granted NOC for Yesintek (solution for subcutaneous injection) 45 mg/0.5ml (prefilled syringe and vial) and 90 mg/ml (prefilled syringe) and Yesintek I.V. (solution for intravenous infusion) 130 mg/26 mL (5mg/mL) in October 2025, it added. The availability of the Yesintek autoinjector provides patients with an option that the originator product does not offer in Canada, the company said . The new format will allow customised treatment approaches across care settings and patient needs, it added. Biocon said Yesintek is indicated for